Wells Fargo lowered the firm’s price target on Biogen to $315 from $365 and keeps an Overweight rating on the shares. The firm’s deep-dive into Skyclarys CHMP decision in early 2024 makes it see high likelihood of success, and favorable risk reward. Skyclarys is as important to Biogen as Leqembi and more important near-term, says Wells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen price target lowered to $295 from $314 at BMO Capital
- Biogen price target raised to $363 from $351 at RBC Capital
- Biogen price target lowered to $310 from $350 at Canaccord
- Best Stocks to Buy Now, 11/9/2023, According to Top Analysts
- Biogen price target raised to $365 from $343 at Wells Fargo